Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development SANTA CLARA, Calif., & BOULDER, Colo. Agilent Technologies Inc. (NYSE: A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for […]

Nottingham, UK – 30th April 2019 – NanoFCM Co., Ltd. today announced that it has established a new facility to support existing and potential users of its Nano-Flow Cytometry platform. The Centre of Excellence is located in Medicity, a biotech incubator in Nottingham, UK. It will allow a close interaction with the European scientific community, as […]

REPROCELL USA has achieved ISO9001:2015 accreditation for quality management utilizing the standard operating protocols established over many years by REPROCELL, Japan, BioServe, Stemgent and Biopta. REPROCELL USA will provide quality bio-repository material, stem cell products and offer services related to pre-clinical genomics, stem cell and drug discovery under this certification.  BELTSVILLE, MD. By achieving certification […]

MELBOURNE, Australia — MGI, a division of global genomics leader BGI Group, announced that Micromon Genomics is the first Australian commercial user of its high-throughput genetic sequencer MGISEQ-2000. Monash University’s Micromon Genomics, a next-generation sequencing facility located in the university’s Biomedical precinct at the Clayton campus in Melbourne, provides sequencing services to Australian researchers, including DNA, RNA, single cell and […]

This new enzyme-based system allows scientists to accurately and sensitively assess DNA methylation without bisulfite treatment, for epigenetics research. IPSWICH, MA — New England Biolabs (NEB®) today announced the launch of NEBNext® Enzymatic Methyl-seq (EM-seq™), an enzyme-based alternative to bisulfite sequencing for methylation analysis. Bisulfite treatment has long been the gold standard for methylome analysis, specifically […]

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products and Services ST. LOUIS — Canopy BiosciencesTM, LLC, a leading provider of gene editing and gene expression products and services, announced today that it has acquired Zellkraftwerk GmbH, a leader in multiplex cytometry. Leveraging […]

LONDON: Freeline, a biotech company focused on developing curative gene therapies for chronic systemic diseases, together with Pall Corporation (Pall), a leading manufacturer of advanced biopharmaceutical processing technology, are pleased to announce the completion of the first full-scale run in Freeline’s newly commissioned Good Manufacturing Practice (GMP) facility located at the Cell and Gene Therapy Catapult […]

MGI Welcomes Collaborators for Diverse Genomes Project, using Single Tube Long Fragment Read (stLFR) Approach to Reduce Cost and Error Rates SEOUL – MGI, a subsidiary of BGI Group, is expanding applications for a new sequencing solution called single tube long fragment read (stLFR) technology, which achieves affordable sequencing, haplotyping, and de novo assembly using unique […]

Strategic collaboration between two organisations represents largest nanopore sequencing project to date, capitalising on recent developments bringing ultra-high yields with PromethION GrandOmics, a leading sequencing company in China, has announced a populational-scale project, dbSV100k, to understand the impact of structural variation on human disease. The project aims to sequence 20,000 human genomes in 2019, with […]

Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our systems strategy in Chromatography and Filtration C Technologies is expected to contribute approximately $16-$17 million in revenue and be accretive […]